The new edition of this highly successful textbook is now available in one carefully integrated volume. A strong clinical emphasis is present throughout from the first section of commonly presenting problems through to the section addressing problems shared with a range of other clinical sub-specialties. The therapy of rheumatic diseases has undergone radical change in the last years with new biological therapies and the new evidence for these therapies is covered extensively. For this edition, all chapters are updated, many are completely new and a considerable number radically revised. Certain chapters are highly innovative in their approach such as Adolescence in transition and there is an almost completely new 5 chapter section on outcomes and issues in delivering rheumatological care. In order to tackle the question of how these clinical problems arise a well written beautifully illustrated account is given of fundamental processes of inflammation. This clearly shows that musculoskeletal diseases in the main arise as a combination of genetic, hormonal, environmental and other factors, which conspire against the individual.
The fourth section deals with the important topic of investigations. Patients with rheumatological disease often suffer a wide variety of complications and this section provides a detailed review of means of assessment. The book also provides a thorough and comprehensive review of the many forms of arthritis and their allied complications, illustrated by many colour photographs. Numerous clinical algorithms are provided throughout to facilitate discussions about management in each of the major forms of arthritis. The publishers would like to thank the following companies whose generous support has enabled us to produce the colour illustrations in this book: Wyeth Pharmaceuticals, Aventis, and Shering-Plough Ltd.
SECTION 1: CLINICAL PRESENTATION OF RHEUMATIC DISEASE; 1.1 Clinical presentations in different age groups; 1.1.1 The adult patient; 1.1.2 The child; 1.1.3 Adolescence and transition; 1.1.4 The geriatric age group; 1.1.5 Principles of examination; 1.1.6 Psychological aspects of rheumatic disease; 1.1.7 Growth and skeletal maturation; 1.2 Common clinical problems; 184.108.40.206 Spinal problems in adults; 220.127.116.11 Spinal problems in children; 1.2.2 Regional problems; 18.104.22.168 The upper limbs in adults; 22.214.171.124. The lower limbs in adults; 126.96.36.199 The arm and leg in children; 1.2.3 Extra-articlular features of rheumatic diseases; 1.3 Views from different perspectives; 1.3.1 Pregnancy and lactation; 188.8.131.52 Pregnancy; 184.108.40.206.2 Antirheumatic drugs in pregnancy & lactation; 1.3.2 The skin and rheumatic disease; 1.3.3 Neurological complications; 1.3.4 The cardiovascular system; 1.3.5 The respiratory system; 1.3.6 The gastrointestinal tract; 1.3.7 Liver, spleen and pancreas; 1.3.8 The endocrine system; 1.3.9 Oncology; 1.3.10 Haematology; 1.3.11 An anaesthetic perspective; 1.3.12 The eye; 1.3.13 The kidney; 1.3.14 Psychiatric issues in rheumatology; SECTION 2: OUTCOMES AND ISSUES IN DELIVERING RHEUMATOLOGICAL CARE; 2.1 Outcome assessment in rheumatology; 2.2 Rehabilitation of adults; 2.3 Rehabilitation of children; 2.4 Rheumatic disease and sexuality; 2.5 Health cost economics and rheumatology; SECTION 3: PATHOPHYSIOLOGY OF MUSCULOSKELETAL DISEASE; 3.1 Genomics and its relevance to rheumatology; 3.2 Molecular abnormalities of collagen and connective tissue; 3.3 Articular cartilage; 3.4 Bone in health and disease; 3.5 The physiology of the joint and its disturbance in inflammation; 3.6 Synovial pathology; 3.7 Skeletal muscle physiology and damage; 3.8 Biomechanics of articulations and derangements in disease; SECTION 4: THE PROCESS OF INFLAMMATION; 4.1 Cells, cytokines and chemokines; 4.2 Leukocyte trafficking in inflammation; 4.3 Specific immune responses; 4.4 Animal models of arthritis; 4.5 Modification of Inflammation; 4.5.1 Non-steroidal anti-inflammatory drugs - old and new; 4.5.2 The place of corticosteroids in the management of rheumatic disease; 4.5.3 Immunosuppressive and other drugs - monotherapy vs combination therapy; 4.5.4 The future targets; SECTION 5: INVESTIGATION OF THE RHEUMATIC DISEASES; 5.1 Acute phase response; 5.2 Biochemistry; 5.3 Microbiology and diagnostic serology; 5.4 Immunology laboratory tests; 5.5 Joint fluid; 5.6 Imaging; 5.6.1 Imaging in adults; 5.6.2. Imaging in children; 5.7 Histopathology; 5.8 Electrophysiology; SECTION 6: THE SCOPE OF RHEUMATIC DISEASE; 6.1 Epidemiology; 6.1.1 Epidemiology and the rheumatic diseases; 6.1.2 Epidemiology of rheumatic diseases in selected non-European populations; 6.2 Infections; 6.2.1 Pyogenic arthritis in adults; 6.2.2 Pyogenic arthritis in children; 6.2.3 Osteomyelitis and associated conditions; 6.2.4 Lyme disease; 6.2.5 Viral arthritis; 6.2.6 HIV infection; 6.2.7 Myobacterial diseases; 6.2.8 Brucellar arthritis; 6.2.9 Parasitic involvement; 6.2.10 Fungal arthritis; 6.2.11 Immunodeficiency; 6.2.12 Rheumatic fever; 6.3 Rheumatic arthritis; 6.3.1 Immunopathogenesis of rheumatoid arthritis; 6.3.2 Rheumatoid arthritis - the clinical picture; 6.3.3 Rheumatoid arthritis - management; 6.3.4 Polyarticular rheumatoid factor positive (seropositive) juvenile idiopathic arthritis; 6.4 Rheumatic arthritis; 6.4.1 Spondylarthropathy, undifferentiated spondylarthritis and overlap; 6.4.2 Spondylarthritis in childhood; 6.4.3 Ankylosing spondylitis; 6.4.4 Psoriatic arthritis; 6.4.5 Reactive arthritis and enteropathic arthropathy; 6.5 Arthropathies primarily occurring in childhood; 6.5.1 Pauciarticular-onset juvenile chronic arthritis; 6.5.2 Systemic-onset juvenile chronic arthritis; 6.5.3 Rheumatoid factor-negative polyarthritis in children; 6.6 Systemic lupus erythematosus; 6.6.1 Systemic lupus erythematosus in adults - clinical features and aetiopathogenesis; 6.6.2 SLE - management in adults; 6.6.3 Paediatric systemic lupus erythematosus; 6.6.4 The antiphospholid antibody syndrome; 6.7 Scleroderma and related disorders in adults and children; 6.8 Polymyositis and dermamyositis; 6.8.1 Polymyositis and dermamyositis in adults; 6.8.2 Polymyositis and dermamyositis in children; 6.9 Sjogren's syndrome; 6.10 Vasculitis; 6.10.1 Classification and epidemiology of vasculitis; 6.10.2 Clinical features of primary ANCA-associated vasculitis; 6.10.3 Treatment of primary ANCA-associated vasculitis; 6.10.4 Secondary vasculitis and vasculitis mimics; 6.10.5 Large vessel vasculitis/gian cell arteritis; 6.10.6 Polymyaligia rheumatica; 6.10.7 Other vasculitides including small vessel vasculitis; 6.10.8 Behcet's syndrome; 6.10.9 Vasculitis in children; 6.11 Overlap syndromes in adults and children; 6.12 Miscellaneous inflammatory conditions; 6.12.1 Amyloidosis; 6.12.2. Familial Mediterranean fever; 6.12.3 Periodic fevers; 6.12.4 Panniculitis; 6.12.5 Neurtophilic dermatoses; 6.12.6 Sarcoidosis; 6.12.7 Macrophage activation syndrome; 6.12.8 The chronic, infantile, neurological, cutaneous and articular syndrome; 6.12.9 Multicentric reticulohistiocytosis; 6.12.10 Hyperlipidaemias; 6.13 Soft Tissue Rheumatism; 6.13.1 Fibromyalgia and diffuse pain syndromes - adult onset; 6.13.2 Local pain syndromes - adult onset; 6.13.3 Pain syndromes - childhood onset; 6.14 Osteoarthritis; 6.15 Crystal arthropathies; 6.16.1 Osteoporosis and osteomalacia; 6.16.2 Paget's disease of bone; 6.16.3 Miscellaneous disorders of bone, cartilage and synovium; 6.16.4 Diseases of bone and cartilage in children; 6.17 Disorders of the spine; 6.17.1 Intevertebral disc disease and other mechanical disorders of the back; 6.17.2 Cervical pain syndromes; 6.18.1 Algodystrophy; 6.18.2 Rheumatic complications of drugs and toxins; SECTION 7: SURGICAL INTERVENTION AND SPORTS MEDICINE; 7.1 Surgery in adults; 7.2 Surgery in children; 7.3 Corticosteroid injection therapy; 7.4 Sports medicine; 7.5 Sports injuries